Robert Davis, Merck CEO

FDA au­tho­rizes new Mer­ck Covid-19 pill de­spite sci­en­tist­s' con­cerns on its mech­a­nism of ac­tion

The FDA on Thurs­day au­tho­rized an­oth­er new pill to treat the Omi­cron vari­ant, this time from Mer­ck.

While Pfiz­er’s an­tivi­ral may prove to be more ef­fec­tive, and Mer­ck’s pill has left some sci­en­tists ques­tion­ing the dan­gers be­hind its mech­a­nism of ac­tion, mol­nupi­ravir will be an­oth­er weapon in the ar­ma­men­tar­i­um of Covid-19 treat­ments for the US in a time of need, as two mAb treat­ments from Re­gen­eron and Eli Lil­ly are no longer ef­fec­tive against Omi­cron, and as sup­plies of a third mAb from Vir/Glax­o­SmithK­line are very lim­it­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.